Apimostinel is an oral NMDA receptor partial agonist.
Apimostinel (NRX-1074) modulates the NMDA receptor in a similar fashion to GLYX-13, but has a synthetic modification to one of the amino acids, conferring increased potency and oral bioavailability[1].
In preclinical models the two compounds both appear to be highly efficacious across a number of CNS disorders[1].
[1]. Naurex's First Orally Active Molecule, NRX-1074, Demonstrates Statistically Significant Improvement in Depression Scores within 24 Hours in Phase 2 Study for Major Depressive Disorder. January 28, 2015.